New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 14, 2013
11:14 EDTSUPN, CTRX, NAV, ULTAOptions with decreasing implied volatility: SUPN CTRX NAV ULTA
News For SUPN;CTRX;NAV;ULTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
10:27 EDTULTAUlta Salon volatility elevated into investor meeting
Ulta Salon October call option implied volatility is at 47, November is at 33, December is at 42; compared to its 26-week average of 34 according to Track Data, suggesting large near term price movement into an Investor meeting on October 15.
09:08 EDTSUPNSupernus announces Paragraph IV ANDA filing for Trokendi XR
Supernus Pharmaceuticals announced that on October 13, the company received a Paragraph IV Notice Letter from Zydus Pharmaceuticals advising Supernus of the filing by Zydus of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Trokendi XR. The product is currently protected by three issued patents that are listed in the FDA's Orange Book and expire no earlier than 2027.
October 13, 2014
11:53 EDTULTAUlta Salon to host investor meeting
Investor meeting to be held in Chicago on October 15 at 11 am. Webcast Link
07:39 EDTCTRXPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
October 9, 2014
09:12 EDTCTRXCatamaran acquisition in-line with expectations, says Leerink
Subscribe for More Information
07:37 EDTCTRXCatamaran acquisition likely to be well-received, says Oppenheimer
Subscribe for More Information
October 8, 2014
16:34 EDTCTRXCatamaran to acquire Salveo Specialty Pharmacy for $260M in cash
Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use